You are here: Home » PTI Stories » National » News
Business Standard

Laurus Labs gets USFDA nod for diabetes drug

Health Medical Pharma

Press Trust of India  |  New Delhi 

Drug firm Laurus Labs today said it has received approval from the US health regulator for its Metformin hydrochloride tablets used for treatment of diabetes.

The company has received approval from United States Food and Drug Administration (USFDA) for Metformin hydrochloride tablets USP in the strengths of 500 mg, 850 mg and 1,000 mg, Laurus Labs said in a BSE filing.

The tablets are generic versions of Bristol-Myers Squibb Company's Glucophage tablets in the same strengths, it added.

The product and API will be commercialised from company's Unit 2 located at Atchutapuram, Visakhapatnam in Andhra Pradesh, Laurus Labs said.

Shares of Laurus Labs today closed at Rs 438.70 per scrip on BSE, down 0.44 per cent from its previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, August 29 2018. 20:36 IST